← Natural Eye Care

Retinitis pigmentosa: what it is, and what the research shows

By Dr. Glen Swartwout, Naturopathic Optometrist

I am retired from licensed practice, and I now write and teach about natural eye care.

This page is education, not a diagnosis or a treatment plan.

Retinitis pigmentosa is a group of inherited diseases of the retina.

The light-sensing cells slowly stop working and die.

A 2018 review gives "a worldwide prevalence of 1:4000."

It says "more than 80 genes have been associated" with the common form.

Source: Non-syndromic retinitis pigmentosa

How it usually progresses

Night vision usually goes first.

Side vision narrows next, which is often called tunnel vision.

Central vision can be lost later in life.

A 2006 review describes loss of "side vision in young adulthood, and central vision in later life."

Source: Retinitis pigmentosa

The pace differs a great deal from one person to the next.

Testing and monitoring

An electroretinogram measures the electrical response of the retina to light.

It can show change "many years before" night blindness is noticed.

Source: Retinitis pigmentosa

Visual field tests map how far side vision reaches.

OCT scans measure a layer of the light-sensing cells called the ellipsoid zone.

In one form of the disease, that layer narrowed about 7% a year.

Its test-to-test variation was smaller than a year's change, unlike field tests.

Source: Ellipsoid zone loss in X-linked retinitis pigmentosa on OCT, JAMA Ophthalmology, 2013

Genetic testing can often find the gene involved.

In 1000 families with inherited retinal disease, a cause was found in "760 families (76%)."

Source: Clinically Focused Molecular Investigation of 1000 Consecutive Families with Inherited Retinal Disease

Knowing the gene matters, because some treatments and trials fit only certain genes.

Problems that can be treated

Fluid can build up in the macula, the centre of sight.

This is called cystoid macular edema.

In one small study, eye drops that lower fluid reduced retinal swelling in 13 of 15 people.

There was no comparison group.

The swelling came back in some people who kept using the drops.

Source: Dorzolamide drops for macular edema in retinitis pigmentosa, American Journal of Ophthalmology, 2006

In a placebo-controlled trial of a similar tablet, swelling improved in "9 of 17 subjects."

Sharpness of sight improved in only a few.

Source: Methazolamide for macular edema in retinitis pigmentosa, Ophthalmology, 1994

Cataract is common in retinitis pigmentosa, often at a younger age.

Cataract surgery can help.

Of 113389 eyes in one database, 72 had the disease.

Those 72 eyes gained less sight than the others.

Swelling of the macula after surgery was more common, at "6.9% of RP eyes."

Source: Cataract Surgery Outcomes in Retinitis Pigmentosa A Comparative Clinical Database Study

Vitamin A

A trial of 601 adults tested vitamin A and vitamin E for four to six years.

Those taking 15000 IU of vitamin A a day had a slower decline in retinal response.

That measure was the electroretinogram, which is separate from useful sight.

In 354 people with stronger starting responses, they were "32% less likely" to lose half of it in a year.

Those taking 400 IU of vitamin E a day were "42% more likely to have a decline."

This was a supplement dose.

The finding says nothing about vitamin E from food.

Sharpness of sight "declined about 1 letter per year in all groups."

Source: A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa

A 2020 Cochrane review was more cautious.

It said "it is uncertain if there is a benefit of treatment with vitamin A or DHA, or both."

It rated much of the evidence as very low certainty.

It found no study showing that vitamins slowed the loss of sharp sight.

Source: Vitamin A and fish oils for preventing the progression of retinitis pigmentosa

High-dose vitamin A has real risks.

Cirrhosis of the liver has been reported with 25000 IU a day taken for six years.

Source: Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases

In pregnancy, birth defects rose above about 10000 IU a day of supplemental vitamin A.

Source: Teratogenicity of high vitamin A intake

Vitamin A is also advised against in a different eye disease, Stargardt disease.

That advice rests mostly on theory.

Source: Vitamin A in Stargardt disease-an evidence-based update

The trial dose of 15000 IU is above the pregnancy level of about 10000 IU.

The vitamin A trial included only adults.

Do not take high-dose vitamin A without your doctor and blood tests.

Never take high-dose vitamin A if you are pregnant or could become pregnant.

Omega-3 and lutein

DHA is an omega-3 fat found in fish.

A trial added DHA for 221 people already taking vitamin A.

DHA "did not, on average, slow the course of disease."

Source: DHA in retinitis pigmentosa with vitamin A treatment, Archives of Ophthalmology, 2004

A four-year trial in one inherited form also found DHA "was not effective."

The authors said dropouts and few disease events limited the trial.

Source: Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial

In people taking vitamin A, eating more fish omega-3 was linked with slower loss of sharp sight.

That finding came from a diet survey, which cannot prove cause.

Source: Omega-3 intake and visual acuity in retinitis pigmentosa with vitamin A, Archives of Ophthalmology, 2012

A trial of lutein in 225 nonsmokers taking vitamin A found no difference on its main field test.

A second field test showed slower loss of mid-side vision, at the edge of significance.

Source: Lutein in retinitis pigmentosa with vitamin A, Archives of Ophthalmology, 2010

N-acetylcysteine

N-acetylcysteine is an antioxidant.

In an early trial of 30 people with no placebo group, sharp sight improved slightly.

The ellipsoid zone did not change.

Nine stomach and bowel side effects were linked to the drug.

Source: N-acetylcysteine and cone function in retinitis pigmentosa, a phase 1 trial, Journal of Clinical Investigation, 2020

The authors said a larger placebo-controlled trial is needed.

As of October 2026, I found no published results from one.

Gene therapy

One gene therapy is approved for disease caused by faults in both copies of the RPE65 gene.

It needs enough living retinal cells to work on.

It is given by surgery under the retina.

In its main trial, "13 (65%) of 20" treated people passed a mobility test in the dimmest light.

No one in the comparison group did.

Source: RPE65 gene therapy with voretigene neparvovec, a randomised phase 3 trial, The Lancet, 2017

The gains were "maintained up to 3 to 4 years."

One treated person had a retinal detachment about four years later.

Source: Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years

This gene causes only a small share of the disease.

A review put it at "1-3% of RP" in the Americas.

Source: Epidemiology of Mutations in the 65-kDa Retinal Pigment Epithelium (RPE65) Gene-Mediated Inherited Retinal Dystrophies: A Systematic Literature Review

Other gene therapies are still in trials, and some have failed.

In one trial for an X-linked form, "The primary microperimetry end point was not met."

It had fewer people than planned.

Ten serious eye-related side effects occurred across the two treated groups.

Source: Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study

Implants and light-sensing therapy

A retinal implant was tested in 30 people with end-stage disease and almost no light perception.

The trial had no comparison group.

After five years, 24 still had working implants.

Source: Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial

In 2021, one blind person regained partial sight after a gene made other retinal cells sense light.

He wore special goggles to use it.

That was one person.

Source: Optogenetic therapy and partial recovery of vision, a case report, Nature Medicine, 2021

Smoking, light and daily life

In a study of 410 people, more smoking was linked with worse sharp sight.

Source: Effect of smoking on macular function and retinal structure in retinitis pigmentosa

Many people with the disease find bright light and glare hard to manage.

In a small study, yellow filters improved some visual function and grey filters made it worse.

That study did not test whether tinted lenses slow the disease.

Source: Tinted filters and visual function in retinitis pigmentosa, Journal of Ophthalmic and Vision Research, 2025

I found no human trial showing that shielding the eyes from light slows the disease.

Low vision services can help with reading, lighting and moving about safely.

In one study, reading speed was "The only modifiable factor" linked with quality of life.

Source: Vision-related quality of life with low vision in retinitis pigmentosa, Japanese Journal of Ophthalmology, 2021

How I think about retinitis pigmentosa

What follows is my own view, from many years in natural eye care.

It is not proven by the studies above.

Retinitis pigmentosa is inherited.

I believe the way genes are expressed matters as well as the genes.

Most people with the disease notice no symptoms in early life.

To me, that suggests a long period when the retina copes.

I believe good care may support it through that time.

Identical twins share the same genes.

A 2011 report described two pairs of identical twin sisters.

In each pair, one twin had retinitis pigmentosa.

The other was unaffected "both clinically and functionally."

Tests found none of the known gene faults they screened for.

The authors said a gene change arising after conception is still possible.

The authors said the explanation remains "elusive."

Source: Discordance for retinitis pigmentosa in two monozygotic twin pairs

To me, these twins suggest that more than genes can decide whether the disease appears.

The report did not study diet or any form of care.

So the approaches I teach aim at a few things.

None of these approaches has been shown in a trial to stop or reverse retinitis pigmentosa.

Use them alongside your eye doctor's care, never instead of it.

What to ask your eye doctor

Ask whether genetic testing could find the gene involved.

Ask whether any clinical trial fits your gene.

Ask about swelling of the macula, and whether it can be treated.

Ask whether high-dose vitamin A suits you, and how your blood will be checked.

Ask about low vision services before daily tasks get hard.

Keep working with your own eye doctor throughout.